In a comprehensive in vitro investigation, it was able to suppress the TNF-α-induced canonical NF-κB activation by inhibiting IκBα degradation and NF-κB binding to DNA (98) in KBM-5 (leukemia), MCF-7 (BC), SCC4 (head and neck cancer), H1299 (LC), U937 (lymphoma), U266, RPMI8226 and MM.1S (myeloma) as well as HCT116 (CRC) cells (Table 1). Here, NFKB1 is linked to head and neck cancer.